• The Need for Follow-through with REAL MS
  • #AAN2018 – Mavenclad Potently Suppresses the Number of Memory B-cells in RRMS, Study Shows
  • #AAN2018 – MS Progresses Quickly in Blacks and May Warrant More Aggressive Treatment
  • Marking the 1-year Anniversary of ‘MS In Motion’
  • #AAN2018 – Review of Phase 3 Trial Data Supports Gilenya as Treatment for Pediatric MS
  • #AAN2018 — ALKS 8700 Shows Promise as RRMS Therapy, Phase 3 Trial Interim Results Suggest
  • This Was Me Before Multiple Sclerosis: A Letter to MS
  • Research Reveals Another Possible Epstein-Barr Virus Link to MS
  • Compound Produced by Immune Cells May Hold Promise for Multiple Sclerosis
  • #AAN2018 – High Fish Consumption Linked to Lower MS Risk
  • #AAN2018 – Celgene to Present Latest Data on Ozanimod’s Safety and Effectiveness
  • Is the MRI Contrasting Agent Gadolinium Safe? (Part 1)